We do not agree with Hansen. The CAPRIE subgroup analyses that we presented in our article did demonstrate a statistically significant reduction in ischemic events with clopidogrel vs aspirin, as was also seen in the overall CAPRIE analysis, though of a different magnitude.1- 6 Furthermore, bleeding rates and rehospitalization for bleeding were lower, not higher, with clopidogrel than with aspirin.2,6 In fact, the whole point of the article was that high-risk subgroups appear to derive a larger degree of benefit from more potent antiplatelet therapy.
Bhatt DL, Hirsh J. The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin—Reply. Arch Intern Med. 2005;165(11):1310–1311. doi:10.1001/archinte.165.11.1310-b